Lobbying Information
Subject Matters
- Consumer Issues
- Economic Development
- Federal-Provincial Relations
- Health
- Industry
- Intellectual Property
- Justice and Law Enforcement
- Science and Technology
- Transportation
Subject Matter Details
Grant, Contribution or Other Financial Benefit
- As part of its renewed biomanufacturing strategy, the Federal Governement has announced its intentions to reinvest in this strategic sector. Sandoz Canada is interested in initiating discussions in this contexte with the potential objective of a joint investment in the life sciences sector.
Legislative Proposal, Bill or Resolution
- Health Canada regarding the Cannabis Act (C-45) for medicinal cannabis
- Innovation, Science & Economic Development Canada regarding export provisions of the Patent Act (pharmaceuticals).
- Innovation, Science & Economic Development, with respect to the Patent Act as it pertains to pharmaceuticals.
- Provide input into the Government of Canada's negotiations regarding the Canada-European Union Comprehensive Economic and Trade Agreement (CETA) and re-negotiation of NAFTA with respect to pharmaceuticals, counterfeit medicines, border measures and intellectual property.
Policies or Program
- Health Canada regarding Patented Medicine Prices Review Board (PMPRB) Reform and National Pharmacare Program
- Health Canada regarding the development and implementation of an approval pathway for Biosimilars as well as pricing policies.
- Health Canada regarding the need for appropriate, dedicated resources for the Therapeutic Products Directorate to meet performance targets for the review of generic drug submissions.
- Health Canada, Innovation, Science & Economic Development Canada and International Trade Canada regarding effective measures to combat counterfeit drugs in Canada and around the world.
- Provide input into Government of Canada's Science and Technology strategy regarding the need for a balanced Intellectual Property regime and the important role competition plays in encouraging innovation.
Regulation
- As a member company, participation in the Canadian Generic Pharmaceutical Association's legal challenge of the 2006 Amendments to Health Canada's Food and Drug Regulations with respect to the extended period of data exclusivity, as well as further proposed amendments to these regulations.
- Health Canada regarding regulation about Requirement for reporting of drug shortages.
- Innovation, Science & Economic Development Canada regarding the need to restore balance to the Patented Medicines (Notice of Compliance) Regulations with respect to pharmaceuticals and address operational concerns including: lack of finality to proceedings under the Regulations and lack of disincentives to discourage abuse of the Regulations.
Communication Techniques
-
Written communication
-
Oral communication
-
Grass-roots communication
Government Institutions
-
Canada Border Services Agency (CBSA)
-
Canada Revenue Agency (CRA)
-
Competition Tribunal (CT)
-
Global Affairs Canada (GAC)
-
Health Canada (HC)
-
House of Commons
-
Innovation, Science and Economic Development Canada (ISED)
-
Justice Canada (JC)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Public Health Agency of Canada (PHAC)
-
Senate of Canada
-
Transport Canada (TC)
-
Treasury Board Of Canada Secretariat (TBS)
In-house Corporation Details
Description of activities
Sandoz, a division of the Novartis group, is a global leader in the field of generic pharmaceuticals and has a portfolio of more than 600 molecules in over 4,000 Stock Keeping Units in various concentrations, formats and delivery systems. Sandoz products are sold in more than 110 countries worldwide.
Sandoz Canada Inc. is one of the very few sites amongst the Sandoz group that combines product development, manufacturing, commercialization and distribution, specializing in the development and manufacture of sterile injectables and ophthalmics. The company currently employs over 700 employees.
Responsible officer name and position during the period of this registration
Michel Robidoux,
President & Chief Executive Officer
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
110 rue de Lauzon
Boucherville, QC J4B 1E6
Canada
Telephone number:
450-641-4903
Ext.
2598
Fax number:
450-641-8615
Parent Company Information
- Novartis Pharma Canada Inc.
-
385 Bouchard Boulevard
Dorval, QC H9S 1A9
Canada
Subsidiary Beneficiary Information
Sandoz Canada Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Sonia Gallo,
Vice-President, Regulatory Affairs |
No public offices held
- Catherine Rousseau,
Senior director, BioGx Market Access |
No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
- Guillaume Lefevre,
Director, Government Affairs |
No public offices held
- Christian Ouellet,
Vice-président Affaires corporatives |
No public offices held